Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto
Jean-Christophe
JC
Département d'Hématologie, Hôpital Morvan, CHU Brest, Brest, France. jcianotto@hotmail.com
Tempescul
Adrian
A
Eveillard
Jean-Richard
JR
Charles
Françoise
F
Berthou
Christian
C
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000139:chemically induced / Q000473:pathology; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide